SenzaGen initiates cooperation with partners in Europe and the US
In this Ring TrialSenzaGen's partners, Eurofins BioPharma Product Testing in Germany and Burleson Research Technologies in the US, will be provided with a number of encoded chemicals to be tested with GARD. The verification of GARD as a robust and reproducible test will open up a new market for SenzaGen, at the same time confirming GARD's unique characteristics.
"With the validation and verification of GARD as a robust test, we can now promote GARD on a broad front in our priority sectors," says Anki Malmborg Hager, CEO of SenzaGen.
GARD has previously undergone both scientific and industrial validation. The test method, which is based on an innovative genomic technology, offers an alternative to existing tests at a time when animal testing is increasingly prohibited.
"With a successful Ring Trial we and our existing customers will have further confirmation of GARD's quality and efficiency, and it will open up new opportunities for us, not least from a regulatory perspective," says Anki Malmborg Hager, CEO of SenzaGen.
The current validation by Eurofins and Burleson will run during the fall and then be reported to EURL ECVAM for review and approval. The result of the validation will provide additional and enhanced opportunities to introduce GARD at various contract laboratories, thus providing increased market penetration.
For more information:
Anki Malmborg Hager, CEO, SenzaGen AB E-mail: amh@senzagen.com Phone: +46 768 284822 |
Brian Rogers, CEO, SenzaGen Inc E-mail: brian.rogers@senzagen.com Phone: +1 530 304 7648 |
About GARD
By analyzing 200 and 389 markers, depending on the test, GARD generates massive amounts of data and delivers results with 90 % prediction accuracy. This can be compared to the gold standard, animal tests in mice, that provides 72 % prediction. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance is an allergen.
About SenzaGen
SenzaGen provides dermal and respiratory in vitro testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company's unique test, GARD, is based on research from the Department of Immuno Technology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.
About Eurofins BioPharma Product Testing, Munich
Eurofins is one of the world's largest laboratory groups with over 23,000 employees in 39 countries and more than 225 laboratories worldwide. The company offers comprehensive service that include testing of drug substance, final product, intermediates, and starting materials for both small and large molecule drug products as well as chemical and microbiological analyses in agriculture, food and environment.
About Buleson Research Technologies
Burleson Research Technologies (BRT) is a Contract Research Organization (CRO) in North Carolina that provides laboratory services to clients from the biotechnology, pharmaceutical, chemical manufacturing, government, and healthcare industries with proof-of-concept, preclinical, and clinical immunotoxicology studies.